Literature DB >> 3698053

Phase II evaluation of weekly cisplatin in metastatic hormone-resistant prostate cancer: a Southeastern Cancer Study Group Trial.

M R Moore, M B Troner, P DeSimone, R Birch, L Irwin.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 3698053

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN： 0361-5960


× No keyword cloud information.
  6 in total

1.  A phase I and pharmacokinetic study of irofulven and cisplatin administered in a 30-min infusion every two weeks to patients with advanced solid tumors.

Authors:  Werner Hilgers; Sandrine Faivre; Stéphanie Chieze; Jérôme Alexandre; François Lokiec; François Goldwasser; Eric Raymond; Carmen Kahatt; Abdelkrim Taamma; Garry Weems; John R MacDonald; Jean-Louis Misset; Esteban Cvitkovic
Journal:  Invest New Drugs       Date:  2006-07       Impact factor: 3.850

2.  Phase II study of oral bis (aceto) ammine dichloro (cyclohexamine) platinum (IV) (JM-216, BMS-182751) given daily x 5 in hormone refractory prostate cancer (HRPC).

Authors:  Tahir Latif; Laura Wood; Cindy Connell; David C Smith; David Vaughn; David Lebwohl; David Peereboom
Journal:  Invest New Drugs       Date:  2005-01       Impact factor: 3.850

3.  The Novel Function of Unsymmetrical Chiral CCN Pincer Nickel Complexes as Chemotherapeutic Agents Targeting Prostate Cancer Cells.

Authors:  Jing-Jing Qu; Lin-Lin Shi; Yan-Bing Wang; Jing Yan; Tian Shao; Xin-Qi Hao; Jia-Xiang Wang; Hong-Yu Zhang; Jun-Fang Gong; Bing Song
Journal:  Molecules       Date:  2022-05-12       Impact factor: 4.927

4.  Chemotherapy in Androgen-Independent Prostate Cancer (AIPC): What's next after taxane progression?

Authors:  Jeanny B Aragon-Ching; William L Dahut
Journal:  Cancer Ther       Date:  2007

5.  Efficacy of carboplatin-taxane combinations in the management of castration-resistant prostate cancer: a pooled analysis of seven prospective clinical trials.

Authors:  M M Regan; E K O'Donnell; W K Kelly; S Halabi; W Berry; S Urakami; N Kikuno; W K Oh
Journal:  Ann Oncol       Date:  2009-07-24       Impact factor: 32.976

6.  Satraplatin in the treatment of hormone-refractory metastatic prostate cancer.

Authors:  Andrew J Armstrong; Daniel J George
Journal:  Ther Clin Risk Manag       Date:  2007-10       Impact factor: 2.423
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.